GeneDx Holdings (WGS) Receivables - Other (2020 - 2026)

GeneDx Holdings (WGS) has reported Receivables - Other for 7 consecutive years, with $4.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables - Other changed N/A year-over-year to $4.8 million in Q2 2026; TTM through Jun 2026 was $4.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.6 million, changed N/A from the prior year.
• Receivables - Other was $4.8 million for Q2 2026 at GeneDx Holdings, up from $4.8 million in the prior quarter.
• Over five years, Receivables - Other peaked at $23.6 million in Q3 2024 and troughed at $25000.0 in Q4 2023.
• A 5-year average of $6.2 million and a median of $3.2 million in 2022 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other surged 2677.78% in 2022 and sank 98.33% in 2023, its largest moves.
• Over 5 years, Receivables - Other stood at $1.5 million in 2022, then slumped by 98.33% to $25000.0 in 2023, then soared by 94192.0% to $23.6 million in 2024, then plunged by 76.41% to $5.6 million in 2025, then declined by 13.72% to $4.8 million in 2026.
• The last three Receivables - Other figures came in at $4.8 million (Q2 2026), $4.8 million (Q1 2026), and $5.6 million (Q4 2025), per Business Quant data.